Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women

European Review for Medical and Pharmacological Sciences

Volumn 7, Issue 5, 2003, Pages 117-125

  Hudita, D ^a   Posea, C ^a   Ceausu, I ^a   Rusu, M ^a  

^a CANTACUZINO INSTITUTE   (Romania)

Author keywords

Climacteric symptoms; Lipid profile; Postmenopausal; Sexual life; Tibolone; Vaginal bleeding

Indexed keywords

CHOLESTEROL; ESTRADIOL; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TIBOLONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BREAST TENDERNESS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; ENDOMETRIUM; FEMALE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEADACHE; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; LIPID METABOLISM; LOW DRUG DOSE; MAMMOGRAPHY; MENOPAUSAL SYNDROME; NAUSEA; NORMAL HUMAN; PARALLEL DESIGN; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEXUAL BEHAVIOR; SIDE EFFECT; SWEATING; THICKNESS; VAGINA BLEEDING; VAGINAL DRYNESS;

EID: 2442661724     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Dennerstein L. Dudley EC, Hopper JL, Guthrie JR, Burger HG. A prospective population-based study of menopausal symptoms. Obstet Gynecol 2000; 96:351-358.
2. De Aloysio D, Gambacciani M, Meschia M, et al. The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group. Atherosclerosis 1999; 147: 147-153.
3. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. Br Med J 1993; 307: 836-840.
4. Knopp RH. Risk factors for coronary artery disease in women. Am J Cardiol 2002; 89 (suppl.12): 28E-34E.
5. Rymer J, Morris EP. Extracts from "Clinical Evidence". Menopausal Symptoms. Br Med J 2000; 321: 1516-1519.
6. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75: 898-915.
7. The Writing Group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199-208.
8. Walsh BW, Schiff I, Rosner B, Greenberg L, Raunikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentration and metabolism of lipoproteins. New Engl J Med 1991; 325: 1196-1204.
9. Tibolone (Livial). A new steroid for the menopause. Drug Ther Bull 1991; 29: 77-78.
10. Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas 1998; 30: 295-305.
11. Modelska K, Cummings S. Tibolone for postmenopausal women: systematic review of randomised trials. J Clin Endocrinol Metab 2002; 87: 16-23.
12. Kicovic PJL, Cortés-Prieto M, Milojevic S, Franchi F. Placebo-controlled cross-over trial study of effects of Org OD 14in menopausal women. Reproduction 1982; 6: 81-91.
13. Nevinny-Stickel J. Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients. Arch Gynecol 1983; 234: 27-31.
14. Bedenek-Jaszmann LJ. Long-term placebo-controlled efficacy and safety study of Org OD 14 in climacteric women. Maturitas 1987; Suppl 1: 25-33.
15. Laan E, van Lunsen RH, Everaerd W. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 2001; 4: 28-41.
16. Geusens P, Dequeker J, Schot LP. Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 1991; 13: 155-162.
17. Bjarnason N, Bjarnason C, Christiansen C. The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 1997; 20: 151-155
18. Berning B, Kuijk JW, Bennink HJ, Kikovic PM, Fauser BC. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 1996; 19: 395-399.
19. Gallagher J, Baylink DJ, NcClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo controlled, dose-finding studies. J Clin Endocrinol Metab 2001; 86: 4717-4726.
20. Walker I, Davidson A, Yates R, McEwan HP. The effect of the synthetic steroid Org OD 14 on fibrinolysis and blood lipids in postmenopausal women. Thromb Haemost 1985; 53: 303-305.
21. Genazzani AR, Petraglia F, Genazzani AD, Bergamaschi M, Grasso A, Volpe A. Effects of Org OD 14 on pituitary and peripheral β-endorphin in castrated rats and post-menopausal women. Maturitas 1987; Suppl 1: 35-48.
22. Bjarnason N, Bjarnason KH, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997; 82: 1752-1756.
23. Lloyd G, McGing A, Patel N, Lumb PJ, Wierzbicki AS, Jackson G. A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens 2000; 14: 99-104.
24. Von Eckardstein A, Crook D, Elbers J, et al. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but dose not impair cholesterol efflux. Clin Endocrinol 2003; 58: 49-58.
25. Cetinkaya MB, Alper T, Kokcu A, Yanik FF, Malatyalioglu E. Tibolone versus four estrogen replacement therapy protocols and plasma lipid levels in postmenopausal women. Int J Gynaecol Obstet 2002; 79: 17-23.
26. Dören M, Rübig HJ, Holzgreve W. Resistance of pelvic arteries and plasma lipids in postmenopausal women: comparative study of tibolone and continuous combined estradiol and norethindone acetate replacement therapy. Am J Obstet Gynecol 2000; 183: 575-582.
27. Berning B, Kuijk HJ, Fauser BC. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 2000; 35: 81-88.
28. Hammar M, Christau J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998; 105: 904-911.
29. Winkler U, Altkemper B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomised study. Fertil Steril 2000; 74: 10-19.
30. McCoy N, Davidson JM. A longitudinal study of the effects of menopause on sexuality. Maturitas 1985; 7: 203-210.
31. Crona NGL, Samsioe UB, Silfverstolpe G. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas 1988; 9: 303-308.
32. Timmer CJ, Houwing NS. Dose proportionality of three different doses of tibolone. Pharmacotherapy 2002; 22: 6-13.
33. Wu MH, Pan Ha, Wang ST, Hsu CC, Chang FM, Huang KE. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001; 4: 314-319.
34. Kannel WB, Wilson PW. Efficacy of lipid profiles in prediction of coronary disease. Am Heart J 1992; 124: 768-774.
35. Wiegratz I, Starflinger F, Tetzloff W, et al. Effect of tibolone compared with sequential hormone replacement therapy on carbohydrate metabolism in postmenopausal women. Maturitas 2002; 41: 133-141.
36. Cagnacci A, Mallus E, Tuveri F, Cirillo R, Setteneri AM, Melis GB. Effect of tibolone on glucose and lipid metabolism in postmenopausal women. J Clin Endocrinol Metab 1997; 82: 251-253.